Association of GSTM3 genotypes with histology, lymph nodes, and location of tumor in esophageal cancer
| GSTM3 AA*, n (%) | GSTM3 AB+BB, n (%) | |||
|---|---|---|---|---|
| Histology | ||||
| Squamous cell carcinoma patients (n = 142)/controls (n = 200) | 112 (78.8%)/176 (88%) | 30 (21.2%)/24 (12%) | ||
| OR (95% CI), P | 1 (reference)* | 1.9 (1.0-3.4), P = 0.03 | ||
| Adenocarcinoma patients (n = 9)/controls (n = 200) | 5 (55.6%)/176 (88.5%) | 4 (44.4%)/ 24 (11.5%) | ||
| OR (95% CI), P | 1 (reference)* | 3.4 (1.1-10.9), P = 0.03 | ||
| Lymph nodes | ||||
| Presence (n = 86)/controls (n = 200) | 72 (83.7%)/176 (88.5%) | 14 (16.3%)/24 (11.5%) | ||
| OR (95% CI), P | 1 (reference)* | 1.6 (0.85-3.1), P = 0.13 | ||
| Absence (n = 41)/controls (n = 200) | 28 (68.3%)/176 (88.4%) | 13 (31.7%)/24 (11.5%) | ||
| OR (95% CI), P | 1 | 3.1 (1.5-6.3), P = 0.001 | ||
| Tumor location | ||||
| Upper (n = 21)/controls (n = 200) | 18 (85.7%)/176 (88.5%) | 3 (14.2%)/24 (11.5%) | ||
| OR (95% CI), P | 1 (reference)* | 2.1 (0.80-5.9), P = 0.12 | ||
| Middle (n = 73)/controls (n = 200) | 58 (79.4%)/176 (88.5%) | 15 (20.5%)/24 (11.5%) | ||
| OR (95% CI), P | 1 (reference)* | 2.2 (1.1-4.4), P = 0.01 | ||
| Lower (n = 48)/controls (n = 200) | 37 (77.0%)/176 (88.5%) | 11 (22.9%)/24 (11.5%) | ||
| OR (95% CI), P | 1 (reference)* | 2.6 (1.2-5.6), P = 0.01 | ||
↵* Age-, gender-, smoking-, and alcohol-adjusted ORs were calculated, using GSTM3 AA as reference.